Sugi Predict

Sugi Predict / Compounds / SCHEMBL4846993

SCHEMBL4846993

SCHEMBL4846993

CSc1ncc(C=O)c(Nc2c(F)cccc2F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CDK9 P50750 3/20 0.36
▸ CCNT1 O60563 2/20 0.36
▸ SRC P12931 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ JAK1 P23458 2/20 0.35
▸ TYK2 P29597 2/20 0.35
▸ JAK3 P52333 2/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ SYK P43405 2/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ LCK P06239 1/20 0.34
▸ ERN1 O75460 1/20 0.34
▸ RXFP1 Q9HBX9 2/20 0.34
▸ PIM1 P11309 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4824670 0.80 CCNA2 (0.47) MAPK1HTTMAPTSYKCDK2
SCHEMBL4716419 0.79 LMNA (0.47) MAPK1HTTSRCMAPTTYK2
SCHEMBL22860146 0.77 HTT (0.51) MAPK1HTTCDK9CCNT1MAPT
SCHEMBL1060749 0.76 CA1 (0.57) MAPK1HTTCDK9CCNT1MAPT
SCHEMBL16003515 0.76 SYK (0.47) MAPK1HTTSRCMAPTSYK
SCHEMBL14163836 0.76 LCK (0.37) CDK9CCNT1SRCJAK1TYK2
SCHEMBL31357045 0.75 MEN1 (0.53) MAPK1HTTSRCJAK1JAK3
SCHEMBL26109543 0.75 MEN1 (0.53) MAPK1HTTSRCJAK1JAK3
SCHEMBL26109252 0.75 CCNA2 (0.39) MAPK1HTTCDK9SYKCDK2
SCHEMBL30597246 0.75 CCNA2 (0.39) MAPK1HTTCDK9SYKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3993802-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Nuvation Bio Inc. (US) 2022-05-11 — — EP disclosed
CN-114340634-A Heterocyclic compounds as kinase inhibitors 诺维逊生物股份有限公司 2022-04-12 — — CN disclosed
WO-2021003314-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2021-01-07 — — WO disclosed
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY 2008-06-12 — — US disclosed
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY 2008-06-12 — — US disclosed
US-7319102-B1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-01-15 — — US disclosed
US-7319102-B1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors DPYD, IL1B, IL6 MAPK1 1957/4885HTT 3447/4885CDK9 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.